The genetically modified suilysin, rSLYP353L, provides a candidate vaccine that suppresses proinflammatory response and reduces fatality following infection with Streptococcus suis
Keywords: استرپتوکوک سویس; CDC; cholesterol-dependent cytolysin; rSLY; recombinant suilysin; STSS; streptococcal toxic shock syndrome; IL-6; interleukin 6; IL-1β; interleukin 1β; TNF-α; tumor necrosis factor alpha; PBS; phosphate buffered saline; HUs; hemoagglutination units; i.